Coverstone Andrea M, Ferkol Thomas W
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, United States.
Front Pediatr. 2021 Jan 11;8:608821. doi: 10.3389/fped.2020.608821. eCollection 2020.
Cystic fibrosis is the most common life-shortening genetic disease affecting Caucasians, clinically manifested by fat malabsorption, poor growth and nutrition, and recurrent sinopulmonary infections. Newborn screening programs for cystic fibrosis are now implemented throughout the United States and in many nations worldwide. Early diagnosis and interventions have led to improved clinical outcomes for people with cystic fibrosis. Newer cystic fibrosis transmembrane conductance regulator potentiators and correctors with mutation-specific effects have increasingly been used in children, and these agents are revolutionizing care. Indeed, it is possible that highly effective modulator therapy used early in life could profoundly affect the trajectory of cystic fibrosis lung disease, and primary prevention may be achievable.
囊性纤维化是影响白种人的最常见的缩短寿命的遗传疾病,临床表现为脂肪吸收不良、生长和营养欠佳以及反复的鼻窦肺部感染。目前美国及全球许多国家都实施了囊性纤维化新生儿筛查项目。早期诊断和干预已改善了囊性纤维化患者的临床预后。具有突变特异性作用的新型囊性纤维化跨膜传导调节因子增强剂和校正剂越来越多地用于儿童,这些药物正在彻底改变治疗方式。的确,在生命早期使用高效调节剂疗法可能会深刻影响囊性纤维化肺部疾病的发展轨迹,而且一级预防或许是可以实现的。